Loading...
•
Mar 31, 2021
Novavax Q1 2021 Earnings Report
Announced financial results and operational highlights for the first quarter ended March 31, 2021.
Key Takeaways
Novavax reported a net loss of $223 million, or $3.05 per share, for the first quarter of 2021. Revenue was $447 million, a significant increase compared to the same period in 2020, driven by increased development activities relating to NVX-CoV2373.
Achieved statistically significant efficacy across Phase 3 UK and Phase 2b South Africa trials for NVX-CoV2373.
Secured additional manufacturing and supply agreements, expanding the global supply chain to over 10 countries.
Looking forward to announcing final data from PREVENT-19 Phase 3 trial and completing regulatory submissions.
Evaluating NVX-CoV2373 in younger populations and continuing to develop booster strategy.